Monsanto the disposition of product lines unrelated to agriculture. In 1985, Monsanto acquired G. D. Searle & Company, a life sciences company that focused on pharmaceuticals, agriculture and animal health. In 1993, its Searle division filed a patent application for Celebrex, which in 1998 became the first selective COX‑2 inhibitor to be approved by the U.S. Food and Drug Administration (FDA). Celebrex became a blockbuster drug and was often mentioned as a key reason for Pfizer's acquisition of Monsanto's pharmaceutical business in 2002. In 1994, Monsanto introduced a recombinant version of bovine somatotropin, brand-named Posilac. Monsanto later sold this business to
March Against Monsanto between industry and government". They also believe that there has been a conflict of interest between former employees of Monsanto who work for the U.S. Food and Drug Administration, and that Monsanto has used their patent rights to create a monopoly of the food supply which has resulted in economic losses by small farmers. Activist and journalist Emilie Rensink, who helped organize the march, said that in her view the appointment of ex-Monsanto executives to head the FDA has resulted in political favoritism, including Monsanto subsidies which have given them an unfair advantage over small farmers. Organizer Canal points to